Literature DB >> 10720547

Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.

L Vernacchio1, S Romero-Steiner, J E Martinez, K MacDonald, S Barnard, T Pilishvili, G M Carlone, D M Ambrosino, D C Molrine.   

Abstract

Children with sickle cell disease were immunized with either 2 doses of 7-valent pneumococcal conjugate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of 23-valent vaccine. Functional antibodies to 7 vaccine serotypes were measured by a flow cytometric opsonophagocytic assay (OPA) and compared with IgG anticapsular polysaccharide antibody concentrations measured by ELISA. Moderate correlations were found between OPA and ELISA antibody titers for all 7 serotypes (r values, 0.41-0.70; P<.001 for all serotypes). After immunization with 23-valent vaccine, geometric mean antibody titers by OPA were significantly higher in the combined schedule group for 5 of 7 vaccine serotypes but were significantly higher for only 2 of 7 serotypes as measured by ELISA. The ability of OPA to show a greater differential response to the 2 immunization schedules used in this study suggests that it may be useful in the evaluation of immunization regimens involving pneumococcal conjugate vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720547     DOI: 10.1086/315307

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.

Authors:  Emmanuel Balandya; Teri Reynolds; Stephen Obaro; Julie Makani
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

Review 2.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection.

Authors:  David Tarragó; Julio Casal; Jesús Ruiz-Contreras; J Tomás Ramos; Pablo Rojo; Harm Snippe; Wouter T M Jansen
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

Review 4.  Should the new pneumococcal vaccine be used in high-risk children?

Authors:  A Finn; R Booy; R Moxon; M Sharland; P Heath
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

5.  Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

Authors:  A Payeras; P Martinez; J Milà; M Riera; A Pareja; J Casal; N Matamoros
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

6.  Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.

Authors:  Catherine Cordonnier; Per Ljungman; Christine Juergens; Johan Maertens; Dominik Selleslag; Vani Sundaraiyer; Peter C Giardina; Keri Clarke; William C Gruber; Daniel A Scott; Beate Schmoele-Thoma
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

7.  Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial.

Authors:  Lykke Larsen; Claus Bistrup; Søren Schwartz Sørensen; Lene Boesby; Charlotte Sværke Jørgensen; Christian Nielsen; Isik Somuncu Johansen
Journal:  Vaccines (Basel)       Date:  2022-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.